Analysis of the cost-effectiveness of the levonorgestrel intrauterine system as alternative to histerectomies in two latin american countries
DOI:
https://doi.org/10.51481/amc.v61i3.1035Keywords:
abnormal uterine bleeding, levonorgestrel intrauterine system, hysterectomy, costeffectivenessAbstract
Objective: The intrauterine system with levonorgestrel has demonstrated a strong endometrial suppressive effect that is useful in a wide variety of gynecological problems. There are numerous studies and reviews of the levonorgestrel intrauterine system that support its use in abnormal uterine bleeding, as well as numerous publications that demonstrate its cost-effectiveness. As far as we know, there are no Latin American publications in this regard. The objective of the present study was to develop a model to assess the costs benefits of the use of the devices as alternative management of abnormal uterine bleeding.
Methods: a pharmacoeconomic model was performed comparing costs and effectiveness with costs of levonorgestrel intrauterine system, insertion, clinical controls plus ultrasounds per month and annually, compared with the direct costs of hysterectomy. Hysterectomy costs were obtained through DRG-WinSIG or direct real costs in Chile and Costa Rica respectively.
Results: Our model demonstratde that when using the levonorgestrel intrauterine systsem as an alternative to hysterectomy in selected patients there is an expenditure of only one third of the costs of performing the hysterectomies in the same patients, even assuming failures with the dispositive. These model did not consider the costs associated with the eventual complications of any surgical act, thus, savings generated by use of the levonorgestrel intrauterine system in these patients could be even greater.
Conclusion: The inclusion of the levonorgestrel intrauterine system in clinical practice guidelines could allow the possibility of reducing hysterectomies in patients refractory to conventional medical treatment and who meet strict inclusion and exclusion criteria. Our models demonstrate that when using the levonorgestrel intrauterine system as an alternative to hysterectomy in selected patients there is a reduction in costs.
Downloads
References
OMS. Criterios médicos de elegibilidad para el uso de anticonceptivos. 5ta edición. Editorial Organización Mundial de la Salud. Génova. 2015.
Peterson HB1, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996; 174: 1161-8.
Lethaby A, Cooke I, Rees M. Progesterone or progestagen releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005; 19:CD002126.
Kriplani A1, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007; 97:190-4.
Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006 19: CD003855.
Andrew M. Kaunitz and Pirjo Inki. The Levonorgestrel-Releasing Intrauterine System in Heavy Menstrual Bleeding. A Benefit-Risk Review. Drugs 2012; 72: 193-215.
Gemzell‑Danielsson K, Inki P, Heikinheimo O Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent insights Expert Rev Obstet Gynecol. 2013; 8: 235-247.
Heavy Menstrual Bleeding. En Guía NICE 44 (National Collaborating Centre for Women's and Children's Health UK. London: RCOG Press 2007: 54-68.
Escobar D y col. Uso del DIU con levonorgestrel como alternativa a la histerectomía en pacientes con alto riesgo quirúrgico. Rev Chilena Obstet Ginecol; 2007; 72: 217-221.
Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelá A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004; 291:1456-63.
Brown PM, Farquhar CM, Lethaby A, Sadler LC, Johnson NP. Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG. 2006 Jul; 113:797- 803.
Lete I, Cristóbal I, Febrer L, Crespo C, Arbat A, Hernández FJ, Brosa M. Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain. Eur J Obstet Gynecol Reprod Biol. 2011; 154:71-80.
Blumenthal PD, Dawson L, Hurskainen R. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet. 2011; 112: 171-8.
Carnero Gómez, R; Rodríguez Barrios, JM. Impacto de los grupos relacionados por el diagnóstico en los ""medical devices"". Economía de la Salud. 2006; 5: número 4.
González Chordá, VM. Maciá Soler, ML. Grupos de pacientes relacionados por el diagnóstico (GRD) en los hospitales generales españoles: variabilidad en la estancia media y el coste medio por proceso. Rev. Enfermería Global 2011; 24: 125-144.
Sebastián Viana, T, et al. Impacto de la codificación de información de enfermería en el peso medio de los grupos relacionados con el diagnóstico y su repercusión en la facturación de un hospital. Gac Sanit. 2009; 23: 55-57.
Janssen C, Scholten P, Heintz P. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977-982.
Larsen L, Coyne K, Chwalisz K. Validation of the menstrual pictogram in womenwith leiomyomata associated with heavy menstrual bleeding. Reprod Sci. 201;20: 680-7.
Downloads
Published
Versions
- 2019-08-29 (2)
- 2019-08-29 (1)
Issue
Section
License
Copyright (c) 2019 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
